Company Overview

Nuo Therapeutics, Inc. is a U.S.-based biotechnology company focused on the development and commercialization of autologous cell-based therapies for wound care and regenerative medicine. The company historically operated within the biotechnology and medical devices industries, with a primary emphasis on chronic and complex wound treatment. Its core technology centered on using a patient’s own blood-derived platelets to stimulate healing.

The company’s principal product was Aurix® System, an autologous platelet-rich plasma (PRP) therapy designed for the treatment of chronic wounds, particularly diabetic foot ulcers. Nuo Therapeutics positioned itself around a personalized medicine approach, leveraging autologous biologics to reduce immunological risk and improve healing outcomes. The company traces its origins to platelet biology research and evolved into a single-product commercial-stage biotechnology firm following regulatory clearance of Aurix.

Business Operations

Nuo Therapeutics generated revenue primarily through the sale and reimbursement of treatments delivered using the Aurix® System, which included both the disposable kits and associated clinical services. Operations were largely concentrated in the wound care segment, with treatments administered in hospitals, outpatient clinics, and long-term care facilities. Revenue depended heavily on reimbursement approvals from government and private payors, making regulatory and coverage decisions central to operations.

The company’s activities were predominantly domestic, with limited evidence of sustained international commercialization. Nuo Therapeutics controlled proprietary know-how related to autologous PRP preparation and application but did not report diversified business units or multiple operating segments. Data inconclusive based on available public sources regarding ongoing manufacturing scale or active commercial operations in recent periods.

Strategic Position & Investments

Strategically, Nuo Therapeutics focused on expanding clinical adoption of Aurix® through additional clinical evidence, reimbursement support, and targeted market penetration in high-incidence chronic wound populations. Growth initiatives historically emphasized clinical trials, health economics studies, and engagement with the Centers for Medicare & Medicaid Services to secure and maintain coverage.

The company did not report a broad portfolio of subsidiaries or a diversified investment strategy. Public disclosures indicate a narrow strategic concentration around Aurix rather than acquisitions or entry into adjacent therapeutic platforms. Data inconclusive based on available public sources regarding active investment activity or pipeline expansion beyond Aurix in the most recent reporting periods.

Geographic Footprint

Nuo Therapeutics was headquartered in the United States, with operational and commercial activities primarily focused on the domestic healthcare market. Its market presence was concentrated in U.S. wound care centers, hospitals, and skilled nursing facilities, reflecting alignment with U.S. reimbursement systems and regulatory pathways.

There is limited verified evidence of material operations or revenue generation outside North America. International expansion was not a significant driver of reported results, and any global footprint beyond the U.S. appears minimal or exploratory based on available public disclosures.

Leadership & Governance

Nuo Therapeutics was led by an executive team with experience in biotechnology, medical devices, and healthcare commercialization. Governance followed a traditional public company structure with oversight by a board of directors, though leadership composition changed over time in response to financial and operational challenges.

Key executives reported in public filings included:

• Brian M. Case – President and Chief Executive Officer
• Charles A. Vorst – Chief Financial Officer
• Christopher M. Keast – Chief Operating Officer

Leadership strategy emphasized clinical validation, reimbursement stability, and disciplined capital management. Data inconclusive based on available public sources regarding current leadership status following later-stage corporate developments.